Controlling immune response expands the possibilities of therapeutic nucleic acid technologies

The idea has been around for a while that selected segments of RNA or DNA could be used therapeutically to affect gene or cell function. The attraction for researchers is the flexibility that these therapeutic nucleic acids' (TNAs) versatility, programmability, and modularity affords them and shows a promising route towards treatment for a wide variety of disorders such as cancer, metabolic disorders, viral infections, cardiovascular and inflammatory diseases. Due to the programmability of RNA and DNA, scientists now are able to embed functional assemblies with controllable immunogenic potential into nucleic acid-based nanoparticles to eliminate the immune response and control the timing of their therapeutic activation.